ES2666720T3 - Composición para prevenir o tratar el cáncer de cuello uterino con un potenciador de la inmunidad contra el virus de papiloma humano - Google Patents

Composición para prevenir o tratar el cáncer de cuello uterino con un potenciador de la inmunidad contra el virus de papiloma humano Download PDF

Info

Publication number
ES2666720T3
ES2666720T3 ES10855938.6T ES10855938T ES2666720T3 ES 2666720 T3 ES2666720 T3 ES 2666720T3 ES 10855938 T ES10855938 T ES 10855938T ES 2666720 T3 ES2666720 T3 ES 2666720T3
Authority
ES
Spain
Prior art keywords
composition
prevent
cervical cancer
against human
human papillomavirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10855938.6T
Other languages
English (en)
Inventor
Young Chul Sung
Sang Hwan Seo
You Suk Suh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genexine Inc
Original Assignee
Genexine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genexine Inc filed Critical Genexine Inc
Application granted granted Critical
Publication of ES2666720T3 publication Critical patent/ES2666720T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una proteína de fusión que comprende: la secuencia de aminoácidos codificada por la secuencia expuesta en la SEQ ID NO: 4.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
9
imagen9
imagen10
imagen11
imagen12
imagen13

Claims (1)

  1. imagen1
    imagen2
ES10855938.6T 2010-08-13 2010-08-13 Composición para prevenir o tratar el cáncer de cuello uterino con un potenciador de la inmunidad contra el virus de papiloma humano Active ES2666720T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/KR2010/005367 WO2012020871A1 (ko) 2010-08-13 2010-08-13 사람 파필로마바이러스 변형체 및 면역 증강제를 포함하는 자궁경부암 예방 또는 치료용 조성물

Publications (1)

Publication Number Publication Date
ES2666720T3 true ES2666720T3 (es) 2018-05-07

Family

ID=45567817

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10855938.6T Active ES2666720T3 (es) 2010-08-13 2010-08-13 Composición para prevenir o tratar el cáncer de cuello uterino con un potenciador de la inmunidad contra el virus de papiloma humano

Country Status (7)

Country Link
US (2) US9000139B2 (es)
EP (1) EP2604629B1 (es)
JP (1) JP5740473B2 (es)
CN (1) CN103180343B (es)
ES (1) ES2666720T3 (es)
PL (1) PL2604629T3 (es)
WO (1) WO2012020871A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2604629T3 (pl) 2010-08-13 2018-08-31 Genexine, Inc. Kompozycja do zapobiegania lub leczenia raka szyjki macicy ze wzmacniaczem odporności przeciwko wirusowi brodawczaka ludzkiego
CN103740741B (zh) * 2014-01-22 2016-08-17 北京工业大学 Hpv18 e6和e7融合基因突变体及其相关生物材料与编码蛋白
CA2957128C (en) * 2014-08-15 2023-09-26 Genexine, Inc. Methods of treating cervical cancer
JP6325751B2 (ja) * 2014-11-04 2018-05-16 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 治療用ｈｐｖ１６ワクチン
CN105753989A (zh) * 2014-12-15 2016-07-13 牛津疫苗医学生物科技（英国）有限公司 人工多抗原融合蛋白及其制备和应用
KR102895580B1 (ko) * 2015-12-09 2025-12-03 진강 메디신 (오스트레일리아) 피티와이 엘티디 치료를 위한 면역조절용 조성물
CN112574317B (zh) * 2017-01-24 2023-12-05 南京益康生物医药有限公司 一种重组蛋白及药物组合物与应用
AU2021261676B2 (en) * 2020-04-24 2025-04-24 Genexine, Inc. Method for treating cervical cancer
US12485165B2 (en) 2022-01-18 2025-12-02 Papivax Biotech Inc. Vaccine combination and method for using the same
JP7385684B2 (ja) * 2022-01-18 2023-11-22 パピヴァックス バイオテック インコーポレイテッド ワクチンの組み合わせ及びその使用方法
US20250188182A1 (en) 2022-03-10 2025-06-12 Genexine, Inc. Triple combination drug dosing therapy for head and neck cancer treatment
WO2024140767A1 (zh) 2022-12-29 2024-07-04 仁景(苏州)生物科技有限公司 用于预防或治疗hpv感染相关疾病的多核苷酸分子

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN015794A0 (en) 1994-12-20 1995-01-19 Csl Limited Variants of human papilloma virus antigens
KR100201584B1 (ko) 1996-07-12 1999-06-15 손경식 사람 파필로마 바이러스 18형 이6 단백질에 대한 인체의 면역성 조절 기능을 갖는 펩타이드
GB9717953D0 (en) 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
EP1214097B3 (en) 1999-09-16 2011-07-20 Eisai Inc. Nucleic acids encoding polyepitope polypeptides
ATE354662T1 (de) 2001-03-23 2007-03-15 Deutsches Krebsforsch Modifizierte hpv e6- und e7-gene und -proteine als impfstoff
KR100900249B1 (ko) 2001-12-07 2009-05-29 포항공과대학교 산학협력단 ＳＩＶｍａｃ239의 면역원성 플라스미드 및 이들을 함유한ＡＩＤＳ ＤＮＡ 백신
EP1553966B1 (en) 2002-10-03 2012-08-01 Wyeth Holdings Corporation Fusion peptides comprising the human papillomavirus e7 and e6 polypeptides and immunogenic compositions thereof
CN1299769C (zh) * 2005-01-31 2007-02-14 中国医学科学院肿瘤医院肿瘤研究所 人乳头瘤病毒和热休克蛋白重组蛋白疫苗及其用途
ATE521626T1 (de) 2005-08-24 2011-09-15 Healthbanks Biotech Co Ltd Fusionsprotein zur inhibierung von gebärmutterhalskrebs
ES2443216T3 (es) 2006-04-19 2014-02-18 Postech Academy-Industry Foundation Proteínas de fusión que comprenden polipéptidos de VPH y péptidos de inmunopotenciación de tratamiento y prevención del cáncer cervicouterino
DE102008010954A1 (de) 2008-02-25 2009-08-27 Cichon, Günter, Prof.Dr. DNA-Vakzine zur Therapie und Prophylaxe von Gebärmutterhalskrebs und seinen prämalignen Vorstufen
PL2604629T3 (pl) 2010-08-13 2018-08-31 Genexine, Inc. Kompozycja do zapobiegania lub leczenia raka szyjki macicy ze wzmacniaczem odporności przeciwko wirusowi brodawczaka ludzkiego

Also Published As

Publication number Publication date
EP2604629A1 (en) 2013-06-19
EP2604629A4 (en) 2014-01-15
JP5740473B2 (ja) 2015-06-24
US20130195905A1 (en) 2013-08-01
US9000139B2 (en) 2015-04-07
US20150239939A1 (en) 2015-08-27
US9399665B2 (en) 2016-07-26
PL2604629T3 (pl) 2018-08-31
JP2013537422A (ja) 2013-10-03
CN103180343A (zh) 2013-06-26
CN103180343B (zh) 2016-01-20
WO2012020871A1 (ko) 2012-02-16
EP2604629B1 (en) 2018-02-28

Similar Documents

Publication Publication Date Title
ES2666720T3 (es) Composición para prevenir o tratar el cáncer de cuello uterino con un potenciador de la inmunidad contra el virus de papiloma humano
ES2606173T3 (es) Composición farmacéutica para el tratamiento y/o la prevención del cáncer
ES2540858T3 (es) Composición farmacéutica para el tratamiento y/o la prevención de cáncer
ES2512141T3 (es) Análogo peptídico de oxintomodulina
ES2486675T3 (es) Análogo de péptido de oxintomodulina
ES2652643T3 (es) Péptidos terapéuticos y su uso contra la corea de Huntington
AR115939A2 (es) Composición que contiene palmitoil-etanolamida ultra-micronizada
CY1120079T1 (el) Υδατικη συνθεση που περιεχει βρωμεξινη
CR20120508A (es) PROTEÍNA DE FUSIÓN ROBO1-Fc Y SU UTILIZACIÓN EN EL TRATAMIENTO DE TUMORES
ES2722799T3 (es) Vacunas contra el cáncer de cerebro basadas en el péptido alfa 2 del receptor de interleuquina-13
BR112015026325A2 (pt) dosagem oral de compostos glp-1
CL2016001405A1 (es) A peptide mixture
MX388904B (es) Agonistas de glucagon/peptido similar al glucagon de tipo 1 (glp-1) para el tratamiento de la obesidad.
ES2488407T3 (es) Preparación farmacéutica que contiene lipasa de origen bacteriano
RU2013134126A (ru) Способ снижения уровня с-концевого телопептида коллагена 2 типа
BR112013032717A2 (pt) coagonistas do receptor de glucagon/glp-1
MX371187B (es) Péptidos terapéuticos.
JO3026B1 (ar) مستضادات ببتيد شبيه الجلوكاجون - 2
MX2011013126A (es) Alimentos medicos con glicomacropeptido para el manejo nutricional de fenilcetonuria y otros trastornos metabolicos.
BR112013031084A2 (pt) meios e métodos para imunoterapia celular ativa de câncer usando células tumorais mortas por alta pressão hidrostática e células dendríticas
ES2572215T3 (es) Anticuerpo neutralizante contra el receptor de prolactina Mat3 y su uso terapéutico
EA201600442A1 (ru) Мягкая фармацевтическая композиция на водной основе, содержащая тапентадол
PH12014501388A1 (en) A recombinant koi herpesvirus (khv) and vaccine for the prevention of a disease caused by khv
CO6741197A2 (es) Proteína de fusión robo1-fc para uso en el tratamiento del hepatocarcinoma
AR100365A1 (es) Composición acuosa que comprende ibuprofeno y paracetamol en combinación, proceso para fabricarla y dispositivo inyector para administrarla